|
 |
European BioPharmaceutical Review
|
<p align="justify" class="feature">The term 'amyloid' was introduced in scientific literature in the mid-19th Century to describe macroscopic abnormalities in organs and tissues of patients afflicted with a variety of clinical syndromes. It took almost a century to realise that these amyloid deposits consisted of fibrillar ultrastructures when examined by electron microscopy (see Figure 1).
Subsequently, numerous studies followed which confirmed that deposits of diverse origin show a similar, fibrillar submicroscopic structure consisting of bundles of straight and rigid fibrils. Several amyloid disorders have since been discovered. Although diverse in etiology and pathogenesis, they all demonstrate this accumulation of large fibrillary protein aggregates which interfere with specificorgan functions.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Global Clinical Outsourcing Partnerships
26-27 March 2009, Mariott Hotel, Brussels
This Jacob Fleming event is designed to promote direct business. It features a two-day educational session with case studies, presentations and interactive sessions. This forum offers networking and the forging of new business partnerships in a unique business-driven environment.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
